An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Phase 3
50
about 2.9 years
18+
6 sites in CA, FL, IL +2
What this study is about
Researchers are testing the long-term safety and clinical benefit of pelabresib in people with hematological or solid tumors. The trial also includes patients who previously took pelabresib, either on a placebo or because they stopped taking it for other reasons, to see if it improves survival.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Pelabresib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Duration of Response (DoR), Progression-free survival (PFS), Treatment-emergent adverse events (TEAEs) and serious TEAEs
Oncology